PT - JOURNAL ARTICLE AU - Bellas-Cotán, Soledad AU - Casans-Francés, Rubén AU - Ibáñez, Cristina AU - Muguruza, Ignacio AU - Muñoz-Alameda, Luis E. TI - Implementation of an ERAS program in patients undergoing thoracic surgery at a third-level university hospital. An ambispective cohort study AID - 10.1101/2020.10.07.20197962 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.07.20197962 4099 - http://medrxiv.org/content/early/2020/10/09/2020.10.07.20197962.short 4100 - http://medrxiv.org/content/early/2020/10/09/2020.10.07.20197962.full AB - Objetive To analyze the effects of the implementation of an ERAS program in patients undergoing pulmonary resection in a tertiary university hospital on the rates of complications and readmission and the length of stay.Methods ambispective cohort study, with a prospective arm of patients undergoing thoracic surgery within an ERAS program versus a retrospective arm of patients before the implementation of the protocol. We recluited 50 patients per arm. The primary outcome was the number of patients with 30-day surgical complications. Secondary outcome included ERAS adherence, no-surgical complications, mortality, readmission, reintervention rates, pain and hospital lenght of stay. We performed a multivariate logistic analysis to study the association of coutcomes with ERAS adherence.Results We found no difference between the two groups in surgical complications [Standard 18 (36%) vs 12 (24%], p =0.19]. ERAS group was significantly lower only in its readmission rate [Standard 15 (30%) vs 6 (12%], p =0.03]. In multivariate analyses, ERAS adherence was the only factor associated with a reduction in surgical complications [OR (95%CI) = 0.02 (0.00, 0.59), p = 0.03] and length of stay [HR (95%CI) = 18.5 (4.39, 78.4), p < 0.001].Conclusions ERAS program was able to decrease the readmission rate at our centre significantly. The adherence to the ERAS protocol influenced the reduction of surgical complications and length of stay.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04579601Funding StatementThe submitted work has not received external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our centre's ethics committee approved our study before the start of patient recruitment, January 2018 Ref: EC021-18_FJD.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesthe Author authorized to include all the content of the work, all data and note links.